www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Amphion partner Myconostica launches new assay in EU and Canada, appoints distributor for Sweden and Finland
Amphion Innovations PLC (AIM: AMP) partner company Myconostica Ltd said it has launched a new version of its MycAssay Pneumocystis product in the European Union and Canada.
Myconostica, in which Amphion holds a 22.14 percent stake, is a UK-based medical diagnostic company specialised in molecular diagnostic tests for life-threatening fungal infections.
MycAssay Pneumocystis is a molecular diagnostic test for the detection of Pneumocystis jirovecii DNA in lower respiratory tract samples. The new kit has improved clinical performance and increased analytical sensitivity and is designed to be used by qualified laboratory staff.
When the new kit is used in conjunction with Myconostica's fungal DNA extraction system, MycXtra, a result can be obtained within 3 hours of sample receipt.
Myconostica also announced that it has signed an agreement with Swedish group Bactus AB to act as the exclusive distributor of its products in Sweden and Finland.
Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
It does not invest in speculative technologies requiring long development timeframes or excessive capital investment; it looks for defensible core intellectual property and know-how for long-term competitive advantage, and growth potential in very large markets of at least US$1 billion in size. Each partner company is chosen with the goal of achieving an exit valuation in excess of US$100 million.
Amphion’s investments also include 38.5 percent in Motif Biosciences, a 19.99 percent stake in Kromek, 15.3 percent in Firestar Software, 8.5 percent in Axcess International, 38.5 percent in Motif Biosciences, 50 percent in MSA Holdings B.S.C., 24.4 percent in M2M Imaging Corp 25 percent in Private Markets and 14.6 percent in WellGen Inc.
It fully controls DataTern, which was established in order to commercialise selected intellectual property opportunities in partnership with Amphion's partner companies.
